Josep M. Llovet, MD is ICREA Research Professor, BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, Univ. Barcelona, Prof. of Medicine and Director of the Liver Cancer Program at the Icahn Mount Sinai School of Medicine, NY. He has published 265 manuscripts in Liver Cancer, including NEJM, Lancet, Nature, Nat. Genet., Cancer Cell and Gastroenterology (IF:3451;citations:51650;h-index:95). Top 1% most cited researcher globally, Thomson Reuters (2014-2017), Educational Councilor (2013-15), President of the ILCA (2011-13), Senior Editor of CCR, he has lectured in 556 international meetings and has been the PI of European grants FP7-HEPTROMIC,HEP-CAR,NIH-NIDDK R01-award, I+D grants and competitive private grants. His achievements are:1.Establish a clinical and molecular classification for HCC. 2.Establish efficacy of chemoembolization and sorafenib for HCC.3.Identification of novel drivers and activated pathways in HCC and ICC.

Research interests

Prof Josep M. Llovet has been working in clinical and translational research in hepatocellular carcinoma (HCC) and cholangiocarcinoma (ICC) for the last 22 years .He is leading international randomized trials in HCC on novel targeted therapies and developing a molecular classification of the disease,understanding the genetic aberrations and signaling pathways involved and in the identification of new molecular targeted therapies. He has organized the HCC Genomic Consortium and the HEPTROMIC Consortium (funded by an FP-7 Grant) that includes several international HCC research centers: IDIBAPS-Hospital Clínic, Ichan Scool of Medicine at Mount Sinai, INSERM, Univ. Tuebingen, Dana-Farber-MIT-Broad Institute and NCI.The main future areas of interest are a) identify biomarkers predicting response to sorafenib and checkpoint inhibitors (nivolumab) or mechanisms of resistance b) translate oncogenic drivers discoveries as targeted therapies in HCC and ICC.